Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD
This article was originally published in The Pink Sheet Daily
Executive SummaryReport from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.
You may also be interested in...
Merck follows Pfizer in signing on to the research collaborative affiliated with insurer UnitedHealth. Research underway or already completed through the collaborative includes a comparison of diabetes drugs and an effort to replicate results of the NIH-sponsored ACCORD trial on cholesterol treatments.
The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.
FDA follows its advisory committee’s recommendation and requires a post-marketing study of Abbott’s fibrate to determine whether combination use with a statin provides a cardiovascular benefit over statin monotherapy in high-risk patients.